Hypercalcemia of Malignancy in Adults

Publication Date: December 20, 2022

Key Points

Key Points

  • Hypercalcemia of malignancy (HCM), a condition associated with high morbidity and mortality, is the most common metabolic complication of malignancies.
  • All adults with HCM should receive treatment with denosumab (Dmab) or an intravenous (IV) bisphosphonate (BP).
  • Adults with calcitriol-mediated HCM should first be treated with glucocorticoids, with the addition of Dmab or an IV BP if glucocorticoid therapy is insufficient.

Treatment

...reatme...

...mmendation 1In adults with HCM, Endocr...

...mmendation 2In adults with HCM, ES suggests...

...ation 3In adults with severe HCM (...

...ndation 4In adults with refractory/recurrent HCM...

...commendation 5In adults with HCM fro...

...ommendation 6In adult patients with hypercalcemia...

...mmendation 7In adult patients with hyperca...

...8In adult patients with hypercalcemi...


...ractice Statements...

...with HCM, adequate hydration with IV fluids is...

UGPS 2In adults with HCM, dental hygiene and ora...

...lts with HCM who receive antiresorptive t...

...with HCM, renal function (creatinine cle...

...with HCM and renal insufficiency (defined as Cr...

...lts with HCM, serum magnesium and phosp...

...n adults with HCM, clinical oncolog...

...8In adults with hypercalcemia due...


...1. Treatment Regimens for Hypercalcemi...


...e 1. Suggested Workflow for the Managem...


...ppendix A: Common Terminology Criteria...